ScripPublic biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A
Pink SheetPharma supply chains still may feel some long-lasting impacts from the proposed BIOSECURE Act, even though the bill appears unlikely to be enacted this year or perhaps ever, although it probably is to
Pink SheetThe pending US election brings much uncertainty for the biopharma industry, but one thing is certain: firms are still going to have to worry about the BIOSECURE Act even after the presidential contest